GHRS Strangle Strategy

GHRS (GH Research PLC), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GHRS (GH Research PLC) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.50B, a beta of 1.28 versus the broader market, a 52-week range of 9.52-24.66, average daily share volume of 218K, a public-listing history dating back to 2021, approximately 50 full-time employees. These structural characteristics shape how GHRS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.28 places GHRS roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on GHRS?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current GHRS snapshot

As of May 15, 2026, spot at $21.54, ATM IV 72.90%, IV rank 5.39%, expected move 20.90%. The strangle on GHRS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on GHRS specifically: GHRS IV at 72.90% is on the cheap side of its 1-year range, which favors premium-buying structures like a GHRS strangle, with a market-implied 1-standard-deviation move of approximately 20.90% (roughly $4.50 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated GHRS expiries trade a higher absolute premium for lower per-day decay. Position sizing on GHRS should anchor to the underlying notional of $21.54 per share and to the trader's directional view on GHRS stock.

GHRS strangle setup

The GHRS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With GHRS near $21.54, the first option leg uses a $22.62 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed GHRS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 GHRS shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$22.62	N/A
Buy 1	Put	$20.46	N/A

GHRS strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

GHRS strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on GHRS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on GHRS

Strangles on GHRS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GHRS chain.

GHRS thesis for this strangle

The market-implied 1-standard-deviation range for GHRS extends from approximately $17.04 on the downside to $26.04 on the upside. A GHRS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current GHRS IV rank near 5.39% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on GHRS at 72.90%. As a Healthcare name, GHRS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to GHRS-specific events.

GHRS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. GHRS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move GHRS alongside the broader basket even when GHRS-specific fundamentals are unchanged. Always rebuild the position from current GHRS chain quotes before placing a trade.

Frequently asked questions

What is a strangle on GHRS?: A strangle on GHRS is the strangle strategy applied to GHRS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With GHRS stock trading near $21.54, the strikes shown on this page are snapped to the nearest listed GHRS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are GHRS strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the GHRS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 72.90%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a GHRS strangle?: The breakeven for the GHRS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current GHRS market-implied 1-standard-deviation expected move is approximately 20.90%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on GHRS?: Strangles on GHRS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the GHRS chain.
How does current GHRS implied volatility affect this strangle?: GHRS ATM IV is at 72.90% with IV rank near 5.39%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.